{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.8","upperLimit":"93.2","value":"87.2"},{"groupId":"OG001","lowerLimit":"71.7","upperLimit":"88.4","value":"81.1"},{"groupId":"OG002","lowerLimit":"72.6","upperLimit":"89.1","value":"81.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"94"}],"units":"Participants"}],"description":"CHR was defined as achieving all of the following measurements: white blood cells (WBC) \\<= institutional upper limit of normal (ULN), platelets less than (\\<)450,000 per cubic millimeter (/mm\\^3), no blasts or promyelocytes in peripheral blood, \\<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \\<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"The analysis included all randomized participant who had been on study for at least 3 months, including the following defined as non-CHR: a) Any participant with end of treatment/early termination (EOT/ET) before 3 months, b) Any participant with CHR not evaluable or with no CHR results at 3 months, and c) Failed to achieve/maintain CHR at Month 3.","reportingStatus":"POSTED","timeFrame":"3 months after the first dose of study treatment","title":"Percentage of Participants With Complete Hematologic Response (CHR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}